Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
NEW YORK, March 08, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Utah on behalf of investors who purchased USANA Health Sciences, Inc. (NYSE:USNA) securities between March 14, 2014 and February 7, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/usana-health-sciences-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (i) the Company's BabyCare Ltd. subsidiary had engaged in improper reimbursement practices in China; (ii) these practices constituted violations of the Foreign Corrupt Practices Act; (iii) as such, the Company’s China revenues were in part the product of unlawful conduct and unlikely to be sustainable; (iv) the foregoing conduct was likely to subject the Company to significant regulatory scrutiny; and (v) as a result of the foregoing, USANA’s public statements were materially false and misleading at all relevant times
On February 7, 2017, post-market, USANA disclosed that “[t]he Company is voluntarily conducting an internal investigation of its China operations, BabyCare Ltd. The investigation focuses on compliance with the Foreign Corrupt Practices Act . . . and certain conduct and policies at BabyCare, including BabyCare's expense reimbursement policies.”
If you suffered a loss in USANA you have until April 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/usana-health-sciences-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
